Timed, sustained release systems for propranolol

Abstract

A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.

What is claimed is:  
     
         1 . A pharmaceutical dosage form comprising timed, sustained release (TSR) beads, wherein said TSR beads comprise: 
 a. a core particle comprising propranolol or a pharmaceutically acceptable salt thereof;    b. a first membrane comprising ethylcellulose surrounding said core to sustain drug release; and    c. a second outer membrane comprising a mixture of ethylcellulose and an enteric polymer, said second membrane providing a lag time before drug release;    d. wherein said TSR beads when tested in a USP type II apparatus at 50 rpm using a 2-stage dissolution medium (first two hours in 700 ml 0.1N HCl at 37° C. followed by dissolution in a pH of 6.8 obtained by the addition of 200 ML of pH modifier) exhibit a dissolution profile substantially corresponding to the following pattern: 
 after 2 hours, 0-20% of the total propranolol is released;  
 after 4 hours, 5-35% of the total propranolol is released;  
 after 6 hours, 10-60% of the total propranolol is released;  
 after 10 hours, 40-90% of the total propranolol is released; and  
 after 16 hours, not less than 60% of the total propanolol is released.  
   
     
     
         2 . A pharmaceutical dosage form as defined in  claim 1 , wherein said dissolution profile substantially corresponds to the following pattern: 
 after 2 hours, 0-10% of the total propranolol is released;    after 4 hours, 5-25% of the total propranolol is released;    after 6 hours, 20-45% of the total propranolol is released;    after 10 hours, 50-80% of the total propranolol is released; and    after 16 hours, not less than 70% of the total propranolol is released.    
     
     
         3 . A pharmaceutical dosage form as defined in  claim 2 , wherein the dissolution profile substantially corresponds to the following pattern: 
 after 2 hours, 0-5% of the total propanolol is released;    after 4 hours, 5-15% of the total propranolol is released;    after 6 hours, 25-35% of the total propranolol is released;    after 10 hours, 55-70% of the total propranolol is released; and    after 16 hours, not less than 75% of the total propranolol is released.    
     
     
         4 . A pharmaceutical dosage form as defined in  claim 1 , wherein the core particle is a non-pareil sugar seed coated with propranolol in a polymeric binder or the core particle is particle prepared by granulation and milling or extrusion/spheronization to form a core particle containing propranolol.  
     
     
         5 . A pharmaceutical dosage form as defined in  claim 1  wherein said enteric polymer is selected from the group consisting of esters of cellulose, polyvinyl acetate phthalate, pH-sensitive methacrylic acid-methylmethacrylate copolymers, shellac and derivatives thereof.  
     
     
         6 . A pharmaceutical dosage form as defined in  claim 5  wherein said enteric polymer is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose succinate and combinations thereof.  
     
     
         7 . A pharmaceutical dosage form as defined in  claim 1  wherein at least one of said first and second membranes further comprises a plasticizer.  
     
     
         8 . A pharmaceutical dosage form as defined in  claim 7  wherein said plasticizer is selected from the group consisting of triacetin, tributyl citrate, tri-ethyl citrate, acetyl tri-n-butyl citrate, diethyl phthalate, dibutyl sebacate, polyethylene glycol, polypropylene glycol, castor oil and acetylated mono- and di-glycerides and mixtures thereof.  
     
     
         9 . A pharmaceutical dosage form as defined in  claim 1  wherein said ethylcellulose and said enteric polymers are present in said outer membrane at a ratio from 10:1 to 1:2.  
     
     
         10 . A pharmaceutical dosage form as defined in  claim 9  wherein said ratio of ethylcellulose to enteric polymer is from 2:1 to 1:1.  
     
     
         11 . A pharmaceutical dosage form as defined in  claim 10  wherein said enteric polymer is hydroxypropyl methylcellulose phthalate.  
     
     
         12 . A pharmaceutical dosage form as defined in  claim 11  wherein said ratio is approximately 1:1.  
     
     
         13 . A pharmaceutical dosage form as defined in  claim 1  wherein said dosage form further comprises immediate release (IR) beads, said IR beads comprising a core particle comprising propranolol.  
     
     
         14 . A pharmaceutical dosage form as defined in  claim 13  wherein said IR beads provide a loading dose by releasing substantially all of the propranolol contained in said IR beads within the first hour after administration of the dosage form.  
     
     
         15 . A pharmaceutical dosage form as defined in  claim 1  wherein the total coating weight of said membranes is from about 10 to 60% of the total weight of said TSR beads.  
     
     
         16 . A pharmaceutical dosage form as defined in  claim 15  wherein said first membrane comprises from about 1.5 to 4% of the total weight of said TSR beads and said second membrane comprises from about 10 to 56% of the total weight of said TSR beads.  
     
     
         17 . A pharmaceutical dosage form as defined in  claim 1  wherein said dosage form contains a total of from 80 mg to 160 mg propranolol or pharmaceutically acceptable salt thereof.  
     
     
         18 . A method for the preparation of the dosage form of  claim 1 , comprising the steps of: 
 a. preparing a propranolol-containing core;    b. coating said core with a plasticized ethylcellulose to form an ethylcellulose membrane around said core;    c. coating said ethylcellulose coated core with a mixture of plasticized ethylcellulose and an enteric polymer to form a Timed, Sustained Release (TSR) coated drug particle; and    d. filling capsules with said TSR beads.    
     
     
         19 . The method of  claim 18  wherein said propranolol-containing core is produced by coating a particle selected from the group consisting of non-pareil seeds, acidic buffer crystals and alkaline buffer crystals with a water soluble film-forming composition comprising propranolol and a polymeric binder.  
     
     
         20 . The method of  claim 18  wherein said propranolol-containing core is produced by granulating and milling and/or by extrusion and spheronization of a polymer composition containing propranolol.  
     
     
         21 . A method of providing a patient with a timed, sustained release of propranolol which comprises administering to said patient a dosage form of  claim 1 .  
     
     
         22 . The method according to  claim 21 , wherein said dosage form is administered orally.  
     
     
         23 . The method according to  claim 22 , wherein said dosage form is administered in the late evening.  
     
     
         24 . The method according to  claim 22 , wherein said dosage form provides a therapeutically effective amount of propranolol by early morning and thereafter provides for sustained release of therapeutic amounts of propranolol.  
     
     
         25 . The method according to  claim 21 , wherein said dosage form provides a T max  at about 12 hours after administration of said dosage form.